Inovio Pharmaceuticals (INO) EBIT (2010 - 2026)
Inovio Pharmaceuticals (INO) posted EBIT of -$21.9 million for Q1 2026, down 25.6% sequentially from -$17.5 million in Q4 2025, and up 12.38% YoY from -$19.5 million in Q1 2025.
Inovio Pharmaceuticals (INO) EBIT (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has reported EBIT for 17 years, with the latest figure at -$21.9 million in Q1 2026.
- Quarterly EBIT rose 12.38% year-over-year to -$21.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$83.7 million (up 20.99% YoY) and the FY2025 annual result came in at -$86.8 million, up 22.76% from the prior year.
- EBIT eased to -$21.9 million in Q1 2026 per INO's latest filing, from -$17.5 million in the prior quarter.
- Over five years, EBIT peaked at -$17.5 million in Q4 2025 and troughed at -$104.1 million in Q2 2022.
- A 5-year average of -$37.2 million and a median of -$31.5 million in 2024 frame the typical range for EBIT.
- The sharpest annual moves came in 2022 and 2023: EBIT sank 36.49% in 2022, then surged 64.43% in 2023.
- Over 5 years, EBIT stood at -$55.9 million in 2022, then surged by 51.04% to -$27.4 million in 2023, then grew by 25.64% to -$20.4 million in 2024, then climbed by 14.2% to -$17.5 million in 2025, then retreated by 25.6% to -$21.9 million in 2026.
- According to Business Quant data, EBIT over the past three periods registered -$21.9 million, -$17.5 million, and -$21.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Inovio Pharmaceuticals | 97.94 Mn | 97.94 Mn | - | -18.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.62 Mn |
| Mar 31, 2026 | -21.95 Mn |
| Dec 31, 2025 | -17.48 Mn |
| Sep 30, 2025 | -21.21 Mn |
| Jun 30, 2025 | -23.08 Mn |
| Mar 31, 2025 | -25.05 Mn |
| Dec 31, 2024 | -20.37 Mn |
| Sep 30, 2024 | -27.35 Mn |
| Jun 30, 2024 | -33.20 Mn |
| Mar 31, 2024 | -31.48 Mn |
| Dec 31, 2023 | -27.39 Mn |
| Sep 30, 2023 | -35.55 Mn |
| Jun 30, 2023 | -37.04 Mn |
| Mar 31, 2023 | -43.95 Mn |
| Dec 31, 2022 | -55.95 Mn |
| Sep 30, 2022 | -35.76 Mn |
| Jun 30, 2022 | -104.14 Mn |
| Mar 31, 2022 | -71.73 Mn |
| Dec 31, 2021 | -105.51 Mn |
| Sep 30, 2021 | -59.95 Mn |